News: JNCE Registers $250M mixed securities shelf (29% of market cap) and 13.3M shares for holders (41% of shares outstanding) - Source TradeTheNews.com
Time: Thursday, March 08, 2018 15:44
Notes: We intend to use the net proceeds from the sale of any securities offered by us under this prospectus for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include, without limitation, research and development expenditures, the acquisition or in-licensing of products or product candidates, business or technologies, collaborations, working capital and capital expenditures. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. We will not receive any proceeds from the sale of any shares of common stock offered and sold by the selling stockholders.
Intraday Maximum Change: $-2.305 - -9.216% Minutes After: 6
Latest Quote: 25.55 Change Since: $-1.765 - -6.91% Days Since: 13
Snapshot of company's key stats at the time of the event
Market Cap: 808,492,614 Shares Outstanding: 32,391,531 Float: 32,291,756
Day's Short Interest: 4,137,022 Short Ratio: 14.33%
Institutional Ownership: 38.1% Insider Ownership: 0.3%
JNCE - Jounce Therapeutics Inc.
Sector: Healthcare - Industry: Biotechnology
Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in transforming the treatment pf cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients.